FDA approves Madrigal Pharmaceuticals drug as first treatment for common NASH liver disease

The FDA's decision means Madrigal has succeeded in a disease area that several larger companies have failed — or are still trying to break into.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.